GlobeNewswire: Curetis Contains the last 10 of 242 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:29:08ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/07/01/2055984/0/en/Curetis-N-V-in-liquidatie-informs-on-publication-of-audited-FY2019-financial-results-and-annual-report.html?f=22&fvtc=4&fvtv=30590 Curetis N.V. in liquidatie informs on publication of audited FY2019 financial results and annual report 2020-07-01T06:35:24Z<![CDATA[Amsterdam, The Netherlands, and Holzgerlingen, Germany, July 01, 2020, 08:30 am CEST - Curetis N.V. in liquidatie (the "Company") today announced the publication of its audited 2019 full year financial results and 2019 Annual Report. Originally scheduled for April 30, 2020, this was delayed due to the impact of the COVID-19 pandemic on the Company’s finance department’s operations, its external advisors, including a purely remote and off-site auditing effort required as part of the liquidation of the Company.]]>https://www.globenewswire.com/news-release/2020/04/30/2024841/0/en/Curetis-N-V-in-liquidatie-informs-on-delay-of-publication-of-audited-FY2019-financial-results-and-annual-report.html?f=22&fvtc=4&fvtv=30590Curetis N.V. in liquidatie informs on delay of publication of audited FY2019 financial results and annual report2020-04-30T05:59:41Z<![CDATA[Amsterdam, The Netherlands, and Holzgerlingen, Germany, April 30, 2020, 08:00 am CET - Curetis N.V. in liquidatie (the "Company") today announced that the publication of its audited 2019 full year financial results and 2019 Annual Report originally scheduled for April 30, 2020 will be delayed to a later date expected in May 2020. The delay is caused by the impact of the COVID-19 pandemic on the Company’s finance department’s operations, its external advisors, including a purely remote and off-site auditing effort required as part of the liquidation of the Company.]]>https://www.globenewswire.com/news-release/2020/04/20/2018346/0/en/Curetis-N-V-in-liquidatie-to-announce-liquidation-distribution-in-advance-and-last-trading-day.html?f=22&fvtc=4&fvtv=30590Curetis N.V. in liquidatie to announce liquidation distribution in advance and last trading day2020-04-20T05:59:05Z<![CDATA[Amsterdam, the Netherlands, Holzgerlingen, Germany April 20, 2020, 8:00 am CEST - Curetis N.V. in liquidatie (the "Company") announces that the liquidators of the Company have resolved upon a liquidation distribution in advance to the respective shareholders of the Company (the “Shareholders”), in an amount equal to the value of 1,622,568 shares of OpGen Inc., a Delaware corporation, common stock (the “OpGen Shares”), which distribution shall be satisfied in kind by transferring the OpGen Shares to the Shareholders pro rata to each share in the Company (each a “Share”) held on May 6, 2020 (the “Distribution Record Date”), and, if applicable, due to the fact that fractions of OpGen Shares shall not be distributed, an amount in cash based on the roundings for each Share held on the Distribution Record Date (the “Distribution in Advance”). The Distribution Record Date has been determined in accordance with the Company’s Shareholder Circular, published on January 27, 2020 (the “Shareholder Circular”). For each Share held on the Distribution Record Date, Shareholders will receive 0.06173599 OpGen Shares. The Distribution in Advance has been approved by the general meeting of the Company at the extraordinary general meeting of the Company, held on March 10, 2020. As a result of the Distribution in Advance, each Shareholder holding Shares on the Distribution Record Date will be credited for the relevant number of OpGen Shares and, if applicable, an amount in cash based on the roundings for each Share held. The Distribution in Advance will be made payable on May 7, 2020.]]>https://www.globenewswire.com/news-release/2020/04/01/2010279/0/en/Curetis-and-OpGen-Close-Business-Combination.html?f=22&fvtc=4&fvtv=30590 Curetis and OpGen Close Business Combination2020-04-01T20:07:41Z<![CDATA[- Following approval of shareholders, companies sign German transfer agreement]]>https://www.globenewswire.com/news-release/2020/03/25/2005979/0/en/Curetis-N-V-Informs-on-OpGen-s-Fourth-Quarter-and-Full-Year-2019-Financial-Results-and-Business-Update.html?f=22&fvtc=4&fvtv=30590Curetis N.V. Informs on OpGen’s Fourth Quarter and Full Year 2019 Financial Results and Business Update2020-03-25T06:59:08Z<![CDATA[Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, March 25, 2020, 08:00 am CET - Curetis N.V. (the "Company" and together with its subsidiaries "Curetis"), a developer of next-level molecular diagnostic solutions, reports that OpGen Inc. (“OpGen”) yesterday, March 24, 2020, reported its audited stand-alone financial and operating results for the three and 12 months ended December 31, 2019 and provided a business update for OpGen and the Curetis Group.]]>https://www.globenewswire.com/news-release/2020/03/16/2000737/0/en/Curetis-Begins-Offering-BGI-s-CE-IVD-Rapid-Test-Kit-for-Coronavirus-in-Europe.html?f=22&fvtc=4&fvtv=30590Curetis Begins Offering BGI’s CE-IVD Rapid Test Kit for Coronavirus in Europe2020-03-16T07:01:58Z<![CDATA[- Rapid real-time PCR test allows testing for SARS-CoV2 in only a few hours]]>https://www.globenewswire.com/news-release/2020/03/10/1998168/0/en/Curetis-N-V-Updates-on-OpGen-Inc-Special-Shareholders-Meeting-Held-on-March-10-2020.html?f=22&fvtc=4&fvtv=30590Curetis N.V. Updates on OpGen, Inc. Special Shareholders’ Meeting Held on March 10, 20202020-03-10T15:15:43Z<![CDATA[Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, March 10, 2020, 16:15 pm CET - Curetis N.V. (the "Company" and together with its subsidiaries "Curetis"), a developer of next-level molecular diagnostic solutions, reports that a Special Meeting of shareholders of OpGen, Inc. (“OpGen”) held today, March 10, 2020, in Washington DC, USA, to approve the business combination of Curetis and OpGen, was adjourned.]]>https://www.globenewswire.com/news-release/2020/03/10/1998062/0/en/Curetis-N-V-Reports-Results-of-the-Extraordinary-General-Meeting-Held-on-March-10-2020.html?f=22&fvtc=4&fvtv=30590Curetis N.V. Reports Results of the Extraordinary General Meeting Held on March 10, 20202020-03-10T13:13:50Z<![CDATA[- Shareholders adopt all proposed resolutions]]>https://www.globenewswire.com/news-release/2020/02/20/1987549/0/en/Curetis-Announces-Preliminary-Unaudited-2019-Condensed-Combined-Key-Financials-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=30590Curetis Announces Preliminary, Unaudited 2019 Condensed Combined Key Financials and Provides Business Update2020-02-20T06:58:49Z<![CDATA[]]>https://www.globenewswire.com/news-release/2020/02/06/1980758/0/en/Curetis-and-Quaphaco-Enter-into-Unyvero-Distribution-Partnership-for-Vietnam.html?f=22&fvtc=4&fvtv=30590Curetis and Quaphaco Enter into Unyvero Distribution Partnership for Vietnam2020-02-06T06:59:50Z<![CDATA[Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, February 6, 2020, 08:00 am CET - Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it has entered into a distribution agreement with Quaphaco for Vietnam. Quaphaco, headquartered in Ho Chi Minh City, is a leading medical equipment supplier in Vietnam that is already working with numerous renowned global IVD manufacturers.]]>